Adalimumab-Aqvh side effects: what 97 FDA adverse event reports show

Adalimumab-Aqvh · Yusimry · 8 reaction terms · 90 drug–reaction co-reports · data 2026-09-14

Drug class

Tumor Necrosis Factor Blocker

FDA label (Established Pharmacologic Class) · compare the class

Brand names

Yusimry

openFDA label

Who reports

97 reports · 25% serious · 2 with death outcome · 62% female

openFDA FAERS counts, all years, deduplication not applied

Used for

YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.

FDA label, Indications and Usage

What it is

Adalimumab-aqvh is a tumor necrosis factor blocker. Adalimumab-aqvh is a recombinant human IgG1 monoclonal antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions.

FDA label, Description section

Boxed warning

SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) ].

FDA label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 4 strongest signals

Reporting / coding artifact 4

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 4 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Device malfunction	28	90.1 65.9–123.2ROR 126.3 · χ² 2,386 / p <1e-300	85.0 EB05 61.7 · IC025 +4.5 3/3 methods agree	Reporting / coding artifact	79% consumer	no trial data cached
Accidental exposure to product	34	73.6 56.1–96.5ROR 112.8 · χ² 2,373 / p <1e-300	70.8 EB05 53.0 · IC025 +4.6 3/3 methods agree	Reporting / coding artifact	76% consumer	no trial data cached
Product complaint	6	52.0 23.9–112.8ROR 55.3 · χ² 251 / p 6e-57	44.9 EB05 22.0 · IC025 +2.0 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Device leakage	10	51.1 28.4–91.9ROR 56.8 · χ² 443 / p 1e-98	46.8 EB05 27.2 · IC025 +2.8 3/3 methods agree	Reporting / coding artifact	–	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Accidental exposure to product	34	73.6 56.1–96.5ROR 112.8 · χ² 2,373 / p <1e-300	70.8 EB05 53.0 · IC025 +4.6 3/3 methods agree	Reporting / coding artifact	76% consumer	no trial data cached
Device malfunction	28	90.1 65.9–123.2ROR 126.3 · χ² 2,386 / p <1e-300	85.0 EB05 61.7 · IC025 +4.5 3/3 methods agree	Reporting / coding artifact	79% consumer	no trial data cached
Device leakage	10	51.1 28.4–91.9ROR 56.8 · χ² 443 / p 1e-98	46.8 EB05 27.2 · IC025 +2.8 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Product complaint	6	52.0 23.9–112.8ROR 55.3 · χ² 251 / p 6e-57	44.9 EB05 22.0 · IC025 +2.0 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Injury associated with device	3	32.2 10.6–98.2ROR 33.2 · χ² 62 / p 1e-15	21.6 EB05 4.1 · IC025 +0.5 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Device defective	3	40.1 13.2–122.1ROR 41.3 · χ² 79 / p 4e-19	27.8 EB05 5.4 · IC025 +0.5 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Device failure	3	42.8 14.0–130.3ROR 44.1 · χ² 84 / p 2e-20	29.8 EB05 5.9 · IC025 +0.5 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Product packaging quantity issue	3	59.4 19.5–181.1ROR 61.3 · χ² 119 / p 6e-28	40.8 EB05 10.8 · IC025 +0.6 3/3 methods agree	Reporting / coding artifact	–	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

✓ A hand-written Bradford Hill causality assessment exists for this drug: TNF-inhibitors (adalimumab) ↔ Drug-induced lupus.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Adalimumab-Aqvh?

In FDA FAERS, the most frequently co-reported reaction terms for Adalimumab-Aqvh are injury associated with device. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Adalimumab-Aqvh have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) ].

Do FAERS signals prove that Adalimumab-Aqvh causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID cd0e7af2-7704-49ce-bde9-f645294b6788, effective 20250516; matched on openfda.generic_name.exact:"ADALIMUMAB-AQVH")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 8 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.